Targeting Relapsed Multiple Myeloma with Elranatamab: A Bispecific Antibody Approach
{{output}}
Elranatamab, an IgG2 bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3 on T cells, is a promising therapeutic option for relapsed or refractory multiple myeloma (RRMM), a hematologic malignancy with limited therapeutic options to date. Elr... ...
